ASCO 2009

 
 
© ASCO/Todd Buchanan 2009
 

The 2009 Annual Meeting of the American Society of Clinical Oncology took place May 29 through June 2, 2009, in Orlando, Florida.

 

Regimen may overcome poor cytogenetics in MM

Mark Fuerst Read Article
Published: 06/22/09

Multiple myeloma cells
Multiple myeloma cells

A phase 2/3 trial reveals a highly effective induction regimen for young, newly diagnosed multiple myeloma patients. Cytoreductive induction followed by high-dose melphalan and autologous stem cell transplant is considered the standard of care for these patients, but success depends on the efficacy of induction. In an attempt to improve induction therapy, researchers tested the combination of bortezomib, intravenous cyclophosphamide, and dexamethasone. [Read Article]

MicroRNA predicts aggressiveness of CN AML

Mark Fuerst Read Article
Published: 06/22/09

Bone marrow aspirate showing AML
Bone marrow aspirate
showing AML

Researchers at The Ohio State University say expression of a specific microRNA found in cytogenetically normal acute myeloid leukemia (CN AML) patients helps predict the aggressiveness of this disease. The team previously showed that CEBPA mutations in CN AML are associated with better outcome and a unique microRNA expression profile, including microRNA-181a upregulation. In this study, they tested whether microRNA-181a expression can predict outcome independently. [Read Article]

Enrolling older patients in clinical trials

HT Staff Read Article
Published: 06/15/09

Enrolling older patients in clinical trials remains a challenge, and as the over-65 population continues to grow, overcoming this challenge becomes increasingly important. At the 2009 Annual Meeting of the American Society of Clinical Oncology, experts addressed the issues surrounding the enrollment of older patients on clinical trials. The presenters discussed the strengths and weaknesses of clinical trial design and the barriers to patient enrollment. [Read Article]

Treating high-risk, relapsed/refractory FL

Mark Fuerst Read Article
Published: 06/14/09

A triple-drug combination of bortezomib, bendamustine, and rituximab is active in heavily pretreated, high-risk patients with relapsed/refractory follicular lymphoma. Previous research showed that bortezomib potentiates the cytotoxic activity of other alkylating agents, such as melphalan, and the drug shows activity when combined with bendamustine to treat patients with advanced multiple myeloma. So researchers hypothesized that combining bortezomib with bendamustine and rituximab might improve responses in relapsed/refractory follicular lymphoma. [Read Article]

Combo highly active in newly diagnosed MM

Mark Fuerst Read Article
Published: 06/13/09

Adding pegylated liposomal doxorubicin hydrochloride to the 3-drug combination of lenalidomide, bortezomib, and dexamethasone (RVD) elicits considerable activity in newly diagnosed multiple myeloma patients, new research shows. Previous research has shown regimens of RVD and of bortezomib, doxorubicin, and dexamethasone (VDD) are among the most active in front-line multiple myeloma. So researchers hypothesized that combining 4 drugs from RVD and VDD into one RVDD regimen might further improve response rates. [Read Article]

New agent appears superior to arsenic trioxide

Bridget Wells Read Article
Published: 06/12/09

DLBCL cells
DLBCL cells

Darinaparsin, an organic arsenic available as an oral and intravenous (IV) agent, is potentially safer and more active than arsenic trioxide, according to a new study. Izidore Lossos, MD, of the University of Miami Miller School of Medicine in Florida, presented the results of a phase 2 study on the IV formulation and 2 phase 1 studies on the oral formulation at the 2009 Annual Meeting of the American Society of Clinical Oncology (ASCO), which took place recently in Orlando.  [Read Article]

Targeted inhibitors have off-target effects

Bridget Wells Read Article
Published: 06/11/09

© ASCO/Todd Buchanan 2009
© ASCO/Todd Buchanan 2009

With a large number of tyrosine kinase inhibitors (TKIs) currently in use and more in development, researchers say it is more important than ever to recognize the off-target effects of these targeted therapies. At the 2009 Annual Meeting of the American Society of Clinical Oncology, Jerome M. Hershman, MD, discussed the effects of TKIs on the thyroid; Thomas L. Force, MD, reviewed the cardiac effects; and Susan Quaggin, MD, discussed effects on the kidneys. [Read Article]

Personalizing thrombosis treatment in cancer patients

HT Staff Read Article
Published: 06/10/09

Personalizing thrombosis treatment in cancer patients is essential to improving outcomes, according to  presentations at the 2009 Annual Meeting of the American Society of Clinical Oncology. Alok A. Khorana, MD, and Charles Francis, MD, of the James P. Wilmot Cancer Center, and Agnes Y. Lee, MD, of the University of British Columbia, discussed risk stratification, thrombosis prevention, treatment of venous thromboembolism, and the impact of anticoagulants on survival. [Read Article]

Girls experience greater cardioprotection with dexrazoxane

Bridget Wells Read Article
Published: 06/09/09

Lipshultz
Steven E. Lipshultz, MD

Dexrazoxane offers significant cardioprotection against doxorubicin-induced effects for pediatric acute lymphoblastic leukemia (ALL) patients. And girls experience a higher level of cardioprotection than boys, new research suggests. Steven E. Lipshultz, MD, of the University of Miami Miller School of Medicine in Florida, presented this research at the 2009 Annual Meeting of the American Society of Clinical Oncology (ASCO), which took place May 29 through June 2. [Read Article]

Antibody induces responses in lymphomas

Bridget Wells Read Article
Published: 06/09/09

Hodgkin’s lymphoma cells
Hodgkin’s lymphoma cells

The new anti-CD30 antibody SGN-35 induces responses in a high proportion of patients with Hodgkin’s lymphoma (HL) and anaplastic large cell lymphoma (ALCL), according to results of a phase 1 dose-escalation trial. Nancy L. Bartlett, MD, of Washington University Siteman Cancer Center in St Louis, Missouri, reported these results at the 2009 Annual Meeting of the American Society of Clinical Oncology (ASCO), which took place recently in Orlando. [Read Article]

Rituximab active in pediatric B-cell NHL

Bridget Wells Read Article
Published: 06/08/09

Alfred Reiter, MD
Alfred Reiter, MD

While rituximab is an integral part of treatment for adults with B-cell non-Hodgkin’s lymphoma (NHL), it has not been evaluated in pediatric patients with the disease, until now. Investigators found single-agent rituximab to be active in this population. Alfred Reiter, MD, of Justus-Liebig-University in Giessen, Germany, presented the results of this phase 2 study at the 2009 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Orlando. [Read Article]

Drug combo shows promise in 1st clinical trial

Mark Fuerst Read Article
Published: 06/08/09

 Bone marrow aspirate showing multiple myeloma
Bone marrow aspirate showing
multiple myeloma

The first clinical trial assessing panobinostat in combination with lenalidomide and dexamethasone shows a thrice-weekly regimen is safe and active in patients with relapsed or refractory multiple myeloma. The combination had shown activity in myeloma cell lines and murine models of the disease, so researchers conducted a study in 22 patients with multiple myeloma. Andrew Spencer, MD, presented results at the 2009 Annual Meeting of the American Society of Clinical Oncology. [Read Article]

New markers improve risk classification in AML

Mark Fuerst Read Article
Published: 06/07/09

Bone marrow aspirate showing AML
Bone marrow aspirate
showing AML

Including new molecular markers can improve the prognostic risk classification of younger de novo cytogenetically normal acute myeloid leukemia (CN AML) patients. Researchers tested patients for FLT3, NPM1, CEBPA, and WT1 mutations and ERG and BAALC expression at diagnosis. Guido Marcucci, MD, of The Ohio State University in Columbus, reported the findings at the 2009 Annual Meeting of the American Society of Clinical Oncology (ASCO). [Read Article]

Defining goals for end-of-life care for cancer patients

HT Staff Read Article
Published: 06/06/09

Defining goals for end-of-life care can minimize aggressive treatment and its associated costs, according to speakers at the 2009 Annual Meeting of the American Society of Clinical Oncology (ASCO). The timing of these discussions and consideration of the patient’s grief state impact initiation of hospice care and quality of death. Holly G. Prigerson, PhD, discussed the Coping with Cancer study, and Jonathan Bergman, MD, presented results on hospice use in men with prostate cancer. [Read Article]

Four drugs better than 3 in newly diagnosed older MM patients

Mark Fuerst Read Article
Published: 06/05/09

Multiple myeloma cells
Multiple myeloma cells

Adding thalidomide to a standard 3-drug regimen for newly diagnosed, older multiple myeloma patients significantly improves the response to therapy, according to a study presented at the 2009 Annual Meeting of the American Society of Clinical Oncology (ASCO). And thalidomide did not increase the incidence of hematologic toxicity. Antonio Palumbo, MD, of Azienda Ospedaliera San Giovanni Battista, Turin, Italy, reported the results for the Italian Multiple Myeloma Network (GIMEMA). [Read Article]

Prior rituximab or early relapse impacts DLBCL prognosis

Mark Fuerst Read Article
Published: 06/04/09

DLBCL cells
DLBCL cells

An international study of nearly 400 relapsed DLBCL patients revealed those who relapse early or received prior rituximab treatment are likely to have a poorer prognosis than late relapsers and those without rituximab exposure. The study compared two widely used regimens of rituximab plus chemotherapy. Christian Gisselbrecht, MD, of Hôpital Saint-Louis, Paris, reported the findings at the 2009 Annual Meeting of the American Society of Clinical Oncology (ASCO). [Read Article]

    {title}

    {icon} {author} Read Article
    Published: {pubDate}

    {summary}